文献速递白血病MDS 与骨髓增殖性肿瘤

新型BET蛋白靶向蛋白降解嵌合体对骨髓增殖性肿瘤后继发性急性髓系白血病细胞的致死活性优于溴结构域抑制剂

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
PubMed 文献 · Leukemia · 2017-02-02

研究对比PROTAC ARV-825与BET抑制剂OTX015对骨髓增殖性肿瘤后继发性急性髓系白血病(post-MPN sAML)细胞的作用。等摩尔浓度下ARV-825持续降解BRD4超过90%,诱导更多凋亡,且对正常CD34+造血祖细胞相对 sparing。ARV-825与芦可替尼联用对sAML细胞呈协同致死作用。

要点

  • ARV-825等摩尔浓度下致BRD4持续深度耗竭超过90%,而OTX015导致BRD4蓄积。
  • ARV-825对培养及患者来源CD34+ post-MPN sAML细胞诱导的凋亡显著多于OTX015。
  • ARV-825与JAK抑制剂芦可替尼联用对sAML细胞呈协同致死作用。

核心结论

  • ARV-825对post-MPN sAML细胞的致死活性优于OTX015,这些发现强烈支持对基于BRD4-PROTAC的联合方案进行体内测试。

研究设计与样本

  • 研究对比PROTAC ARV-825与BET抑制剂OTX015在培养及患者来源CD34+ post-MPN sAML细胞及CD34+正常造血祖细胞中的作用。
  • 采用RNA-Seq、反向蛋白阵列和质谱流式CyTOF分析mRNA和蛋白表达变化。
  • 在表达荧光素酶的HEL92.1.7细胞植入的NSG小鼠中对比ARV-771与OTX015对白血病负荷和生存的影响。

主要发现

  • 等摩尔浓度ARV-825致BRD4持续深度耗竭超过90%,而OTX015导致BRD4蓄积。
  • ARV-825在培养和患者来源CD34+ post-MPN sAML细胞中诱导的凋亡显著多于OTX015,同时对CD34+正常造血祖细胞相对sparing。
  • 相比OTX015,ARV-825更持久地耗竭c-Myc、CDK4/6、JAK2、p-STAT3/5、PIM1和Bcl-xL,并升高p21和p27水平。
  • 相比OTX015,ARV-771更大幅度降低白血病负荷并进一步改善植入表达荧光素酶HEL92.1.7细胞的NSG小鼠生存。
  • ARV-825与芦可替尼联用对已建立及患者来源CD34+ sAML细胞呈协同致死作用;ARV-825在体外产生的芦可替尼持续存活或耐药sAML细胞中诱导高水平凋亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The PROTAC (proteolysis-targeting chimera) ARV-825 recruits bromodomain and extraterminal (BET) proteins to the E3 ubiquitin ligase cereblon, leading to degradation of BET proteins, including BRD4. Although the BET-protein inhibitor (BETi) OTX015 caused accumulation of BRD4, treatment with equimolar concentrations of ARV-825 caused sustained and profound depletion (>90%) of BRD4 and induced significantly more apoptosis in cultured and patient-derived (PD) CD34+ post-MPN sAML cells, while relatively sparing the CD34+ normal hematopoietic progenitor cells. RNA-Seq, Reverse Phase Protein Array and mass cytometry 'CyTOF' analyses demonstrated that ARV-825 caused greater perturbations in messenger RNA (mRNA) and protein expressions than OTX015 in sAML cells. Specifically, compared with OTX015, ARV-825 treatment caused more robust and sustained depletion of c-Myc, CDK4/6, JAK2, p-STAT3/5, PIM1 and Bcl-xL, while increasing the levels of p21 and p27. Compared with OTX015, PROTAC ARV-771 treatment caused greater reduction in leukemia burden and further improved survival of NSG mice engrafted with luciferase-expressing HEL92.1.7 cells. Co-treatment with ARV-825 and JAK inhibitor ruxolitinib was synergistically lethal against established and PD CD34+ sAML cells. Notably, ARV-825 induced high levels of apoptosis in the in vitro generated ruxolitinib-persister or ruxolitinib-resistant sAML cells. These findings strongly support the in vivo testing of the BRD4-PROTAC based combinations against post-MPN sAML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Saenz DT, Fiskus W, Qian Y, et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017. PMID: 28042144. doi:10.1038/leu.2016.393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。